Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $784,513 | $724,508 | $695,420 | $730,518 |
| % Growth | 8.3% | 4.2% | -4.8% | – |
| Cost of Goods Sold | $510,539 | $438,255 | $439,529 | $467,645 |
| Gross Profit | $273,974 | $286,253 | $255,891 | $262,873 |
| % Margin | 34.9% | 39.5% | 36.8% | 36% |
| R&D Expenses | $63,352 | $49,981 | $41,807 | $56,117 |
| G&A Expenses | $0 | $0 | $0 | $94,287 |
| SG&A Expenses | $137,815 | $124,266 | $118,288 | $128,687 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $34,400 |
| Other Operating Expenses | $72,924 | $634 | -$4,551 | $2,276 |
| Operating Expenses | $274,091 | $174,881 | $155,544 | $187,080 |
| Operating Income | -$117 | $111,372 | $100,347 | $75,793 |
| % Margin | -0% | 15.4% | 14.4% | 10.4% |
| Other Income/Exp. Net | -$5,106 | -$59,661 | -$62,861 | -$91,112 |
| Pre-Tax Income | -$5,223 | $51,711 | $37,486 | -$15,319 |
| Tax Expense | -$23,355 | $16,101 | $12,868 | $5,423 |
| Net Income | $2,369 | $22,417 | $12,195 | -$31,081 |
| % Margin | 0.3% | 3.1% | 1.8% | -4.3% |
| EPS | 0.008 | 0.071 | 0.039 | -0.1 |
| % Growth | -89.5% | 82.1% | 139.2% | – |
| EPS Diluted | 0.008 | 0.07 | 0.038 | -0.1 |
| Weighted Avg Shares Out | 314,168 | 313,739 | 311,054 | 309,850 |
| Weighted Avg Shares Out Dil | 324,754 | 322,363 | 323,961 | 309,850 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $62,814 | $65,101 | $56,939 | $61,662 |
| Depreciation & Amortization | $54,073 | $60,113 | $60,159 | $66,130 |
| EBITDA | $111,664 | $176,925 | $154,584 | $112,473 |
| % Margin | 14.2% | 24.4% | 22.2% | 15.4% |